Plasma-cell proliferations span a wide spectrum, ranging from plasma-cell dyscrasia to overt multiple myeloma. 1, 2 Plasma-cell dyscrasia can be rather mild, such as that associated with the low levels of monoclonal protein seen in monoclonal gammopathy of undetermined signi cance. However, regardless of the degree of plasma-cell proliferation, renal manifestations are frequently the initial presentation of the underlying process. Moreover, even though the circulating monoclonal protein has a systemic outreach, and many patients may have extrarenal manifestations, clinical symptomatology is led by prominent renal involvement with severe renal failure. 1, 2 Renal pathology associated with the presence of a paraprotein can be quite diverse, ranging from tubular pathology (such as light chain cast nephropathy or proximal light chain tubulopathy) to tubulointerstitial nephritis to glomerular abnormalities. 1 -6 e last can be associated with extracellular deposition of the actual paraprotein in the form of brillar or non-brillar deposits. Fibrillar deposits are seen in light chain-derived amyloid (AL) and are Congo red positive and birefringent under polarized light. In contrast, non-fibrillar deposits are seen in light chain deposition disease (LCDD), are Congo red negative, and have a granular or ' punctate ' ultrastructural appearance (reviewed by Ronco et al. 1 and Picken 2 ). In rare patients, tissue deposits can be derived from heavy (or light and heavy) chains. Therefore, the terms ' AH' (for amy loid derived from the heavy chain) and 'monoclonal immunoglobulin disease' have been coined. e latter term encompasses LCDD as well as rare entities such as heavy chain deposition disease and light and heavy chain deposition disease.
Interestingly, not every patient with paraprotein develops tissue deposits. Although the exact statistics are di cult to obtain, it is estimated that, among patients with multiple myeloma, only 11 % will develop AL and only 5 % will be 2, 7 Thus, certain light chains, such as VI, are overrepresented in patients with AL. In general, light chains predominate in AL, whereas light chains predominate in LCDD. Interestingly, although deposition of a monoclonal protein occurs in both AL and LCDD, the pathomechanism is di erent. Elongation of the brils seems to play a role in AL, while tissue deposition in monoclonal immunoglobulin disease appears to be associated with one-step precipitation. Moreover, in AL, accumulation of the monoclonal protein is associated with depletion of the extracellular matrix. In contrast, in mature LCDD, there is striking accumulation of the extracellular matrix-forming nodules, reminiscent of those seen in diabetic nephropathy and membranoproliferative glomerulone phritis type I. Importantly, however, early stages of AL, as well as LCDD, may be inconspicuous by light microscopy (LM) and detectable only by special studies. us, for diagnosis as well as for differential diagnosis, immunostains -in particular, immunofluorescence-are critical. 1,2,4 -6 Proteinuria and renal failure dominate the clinical presentation. In most cases, renal function declines rapidly, which underscores the urgent need not only to diagnose the process early but also to instigate e ective therapy. us far, aggressive chemotherapy has been the main approach to the treatment of patients with paraprotein. 8 -10 Although instances of improvement of renal function have been reported, in particular in patients who had good renal function at the time of represents the classical lesion found in advanced LCDD.
e article by Keeling and Herrera 11 is not only about peculiar mesangial alterations in LCDD but actually transcends this topic to provide crucial insights relating to mesangial-cell pathobiology. e responses that mesangial cells can exhibit to various injurious agents are limited.
e described behavior observed when mesangial cells were incubated with certain glomerulopathic light chains must repeat itself when they are confronted with other injurious agents, at least to a certain extent. e interaction with glomerulopathic light chains is governed by purported receptors located on the mesangial-cell membrane. ese receptors may be shared by other mediators of glomerular injury. What is most interesting is that light chains isolated from patients with light chain cast nephropathy (that is, tubulopathic light chains) associated with plasma-cell dyscrasia do not alter mesangial homeostasis, which clearly shows that they do not interact with mesangial-cell receptors.
Although Keeling and Herrera 11 focus on mesangial sclerosis associated with LCDD, there are also potential lessons to be learned about the progression of glomerular injury in general. Transforming growth factor-is widely increased in progressive renal disease and is therefore an attractive target for modulation of renal injury progression. Animal studies have shown (reviewed by Ma and Fogo 12 ) that even when sclerosis has developed, with accumulation of extracellular matrix, this lesion may be remodeled with a change in glomerular homeostasis. Now, Keeling and Herrera 11 have shown that this is possible with human mesangial cells grown in culture.
is seminal contribution to the understanding of the pathogenesis of LCDD is most welcome, since new therapies aimed at targeting key steps in the cascade of events may be designed for use in combination with a reduction of circulating glomerulopathic light chains. is therapeutic approach may help ameliorate, or even totally inhibit, the progression of renal damage and allow repair of the damaged glomerulus. As we are diagnosis, many patients succumb to progressive renal disease despite chemotherapy. us, additional treatments are highly desirable. Understanding the pathogenesis of LCDD may help in designing new therapies for use in combination with a reduction of circulating glomerulopathic light chains. e article by Keeling and Herrera 11 (this issue) dissects the molecular events that take place in the kidneys of patients with LCDD using an in vitro human mesangial cell culture model. is model closely reproduces events that occur in vivo , as seen in renal biopsies from these patients. Human mesangial cells are incubated with light chains puri ed from the urine of patients with LCDD (LCDDLCs), and the sequential events that occur are monitored with the use of a variety of morphologic and molecular techniques.
Crucial events in the process, clearly delineated in the model, include the initial activation of platelet-derived growth factor-, resulting in mesangial-cell proliferation, followed by transforming growth factor-activation, leading to an increase in extracellular matrix and a negative-feedback loop inhibiting cellular proliferation (Figure 1 ). e main extracellular matrix component deposited in the expanded mesangium is tenascin-C, a complex protein.
Normally, tenascin-C is destroyed predominantly by metalloproteinase-7 (MMP-7) in combination with minor contributions from other MMPs, most notably MMP-1 and MMP-3. It is interesting that MMP-7 appears to be adequately produced by mesangial cells in LCDD, but its release from the cells is impaired, preventing it from reaching the matrix, where it normally acts on the deposited tenascin. It is also interesting that the mere addition of LCDD-LCs to mesangial cells in culture increased the expression of tenascin-C in mesangial nodules, 11 and this increase was even higher with the addition of MMP-7 and its inhibitor. LCDD-LCs induce phenotypic changes in the mesangial cells, which in turn secrete tenascin-C in abundance. LCDD-LCs cannot be catabolized by mesangial cells, most likely because of their physicochemical properties. Tenascin-C and LCDD-LCs colocalize in the center of the mesangial nodules. As a result, they become entrapped and nondegradable. e end result is mesangial expansion with formation of nodules containing large quantities of tenascin-C at their centers, the typical finding in nodular glomerulosclerosis, which facing a true epidemic of glomerular sclerosis, dissecting its pathogenesis, one pathway at a time, is a welcome step. We cannot devise effective therapies for glomerular sclerosis unless we know its pathomechanism. We need to identify and learn how to control the responsible receptors triggering the pathways to sclerosis.
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The author declared no competing interests. keratinocytes? Vitamin D is critically important for the development, growth, and maintenance of a healthy skeleton from birth until death. e major function of vitamin D is to maintain calcium homeostasis. It accomplishes this by increasing the e ciency with which the intestine absorbs dietary calcium. When there is inadequate calcium in the diet to satisfy the body ' s calcium requirement, vitamin D and other humoral and local factors communicate to the osteoblasts that then signal osteoclast precursors to mature and dissolve the calcium stored in the bone. 2 Vitamin D 3 is metabolized in the liver to produce 25-hydroxyvitamin D 3 (25(OH)D) and then in the kidney to 1,25-dihydroxyvitamin D 3 (1,25(OH) 2 D), the biologically active form of the vitamin. 1,25(OH) 2 D acts on its receptors, the vitamin D receptors, which are present not only in the intestine and bone, but in a wide variety of other tissues, including the brain, heart, stomach, pancreas, activated T and B lymphocytes, skin, and gonads. Muscle function, innate immunity, cellular growth and maturation, immunomodulation, and insulin secretion, as well as the regulation of calcium, phosphorus, and bone meta bolism, are all a ected or controlled by vitamin D ( Figure 1 ). 1,25(OH) 2 D is one of the most potent substances to inhibit proliferation of both normal and hyperproliferative cells and induce them to mature. It is also recognized that apart from the 1,25(OH) 2 D synthesized and Vitamin D is an ancient hormone identi ed in the ocean-dri ing organisms, the plankton that evolved over 750 million years ago. Without plankton there would be no life, and phytoplankton have the essential capacity not only to recycle carbon but also to synthesize vitamin D. The ingestion of plankton in the depths of the oceans provides the vitamin D content of fish, and hence a plentiful supply for fish-eating humans. In the cauldrons of time Homo sapiens evolved half a billion years later, developed remarkable cognitive neurodevelopment, and retained the ability to e ciently synthesize vitamin D 3 or cholecalciferol when exposed to the ultraviolet B rays of sunlight. However, we are constrained by a limited opportunity to bare our bodies to the joys of the sun, clouded by a concern for the harmful e ects of excess ultraviolet B rays. Transplant patients are well advised to limit their exposure to the ultraviolet B rays and their potentially damaging e ects because a well-documented complication of immunosuppressive therapy is the far greater incidence of skin cancers. 1 But what about the bene cial e ects of ultraviolet B in initiating the photosynthesis of cholecalciferol in their
ACKNOWLEDGMENTS

